Michel Vounatsos, Biogen CEO (via YouTube)
April 23, 2020 09:01 AM EDTUpdated April 24, 07:07 AM
People
Bioregnum
Opinion

Bio­gen’s top ex­ec­u­tive crew has a big cred­i­bil­i­ty is­sue. And they seem de­ter­mined to make it worse

First came the pan­dem­ic “su­per­spread­er” event at the Mar­riott Long Wharf that cre­at­ed a sim­mer­ing pub­lic re­la­tions night­mare for Bio­gen $BI­IB. And now here …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times